Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Duodenal or ampullary adenoma greater than or equal to 10mm Duodenal or ampullary adenoma that is suitable for endoscopic mucosal resection Medically fit for anesthesia, endoscopy, and EMR Able to provide Informed Consent 18 years or older, male and female~Exclusion Criteria:~Duodenal or ampullary adenoma \<10mm Duodenal or ampullary adenoma that is not suitable for endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to provide informed consent Less than 18 years old Allergy to Octreotide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: EXPERIMENTAL): Octreotide 100mcg subcutaneous every 8 hours for 5 days
- no octreotide (Type: OTHER): No Octreotide

Based on this trial design, predict the completion outcome and termination type (if applicable).